Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...

IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...

The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

A late night, another patient in distress or a tiff with the spouse—patients will never know the worries that weigh on their ...

SNS Insider Reports: Retinal Surgery market to Grow at 6.05% CAGR, Fueled by Minimally Invasive Tools, Aging Population & Increasing diabetic Retinopathy Cases ...

However, the study provides limited new insights into the relationship between retinal lamination defects and overall retinal function. Neural lamination is a common feature of the central nervous ...

Nagpur: India is facing an alarming rise in cases of Retinopathy of Prematurity (ROP), a condition that can cause irreversible blindness in premature .

Results: An atrophic retinal hole was found in one boxer ... It should be made mandatory for all boxers to have a complete ophthalmological examination at the beginning of their careers and ...

Prematurity is the primary risk factor for developing ROP because of incomplete vascularization of the retina. The vessels are fragile and immature with avascular areas at the periphery.